{"id":55225,"date":"2026-01-23T05:58:02","date_gmt":"2026-01-22T21:58:02","guid":{"rendered":"https:\/\/flcube.com\/?p=55225"},"modified":"2026-01-23T05:58:03","modified_gmt":"2026-01-22T21:58:03","slug":"taigen-and-joincare-partner-on-tg-4318-dpp1-inhibitor-for-bronchiectasis-in-greater-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55225","title":{"rendered":"TaiGen and Joincare Partner on TG\u20114318 DPP1 Inhibitor for Bronchiectasis in Greater China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>TaiGen Biotechnology<\/strong> and <strong>Joincare Pharmaceutical Group<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600380:SHA\">SHA: 600380<\/a>) announced a licensing agreement for the collaborative development and commercialization of <strong>TG\u20114318<\/strong>, a novel <strong>Dipeptidyl Peptidase 1 (DPP1) inhibitor<\/strong> for bronchiectasis, covering <strong>Greater China<\/strong> (Mainland China, Hong Kong, and Macau).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-partnership-terms\">Deal Structure &amp; Partnership Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>TaiGen Biotechnology (4157)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Joincare Pharmaceutical Group (600380.SH)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>TG\u20114318 (DPP1 inhibitor)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Bronchiectasis (primary)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Greater China \u2013 exclusive rights<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Preclinical; preparing for clinical trials<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Upfront signing fee + development milestones + sales royalties<\/td><\/tr><tr><td><strong>Responsibilities<\/strong><\/td><td>Joincare leads clinical trials, manufacturing, and commercialization in Greater China; collaborates on global development<\/td><\/tr><tr><td><strong>Strategic Context<\/strong><\/td><td>Second innovative drug collaboration following TG\u20111000 influenza antiviral partnership<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>DPP1 inhibitor<\/strong> with a novel mechanism of action targeting neutrophil\u2011mediated inflammation in bronchiectasis<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Best\u2011in\u2011class potential due to selective DPP1 inhibition and favorable preclinical safety profile<\/li>\n\n\n\n<li><strong>Clinical Progress:<\/strong> Currently in preclinical evaluation; IND\u2011enabling studies underway to support global clinical trial initiation<\/li>\n\n\n\n<li><strong>Market Position:<\/strong> First\u2011in\u2011class DPP1 inhibitor approach for bronchiectasis in China, addressing high unmet need in rare respiratory disease<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bronchiectasis Burden:<\/strong> Estimated <strong>1.5\u20132.0\u202fmillion patients<\/strong> in Greater China suffer from bronchiectasis, with limited approved therapies beyond symptomatic management.<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts forecast <strong>\u00a5500\u2013700\u202fmillion<\/strong> (US$70\u2013100\u202fmillion) peak annual sales in Greater China by 2030, assuming successful Phase\u202fIII trials and NRDL inclusion.<\/li>\n\n\n\n<li><strong>Strategic Synergy:<\/strong> Joincare\u2019s 4,000\u2011person respiratory sales force and hospital network provide immediate commercial infrastructure; TaiGen retains upside via milestones and royalties.<\/li>\n\n\n\n<li><strong>Global Ambition:<\/strong> Partnership includes joint global development, positioning TG\u20114318 for potential ex\u2011China licensing opportunities in US\/EU markets.<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> Second collaboration underscores successful track record between the companies, reducing execution risk for investors.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding development timelines, clinical outcomes, and revenue projections for TG\u20114318. Actual results may differ materially due to regulatory risks, clinical trial outcomes, and competitive dynamics in the respiratory market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>TaiGen Biotechnology and Joincare Pharmaceutical Group (SHA: 600380) announced a licensing agreement for the collaborative&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[676,965,966],"class_list":["post-55225","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-joincare-pharmaceutical","tag-sha-600380","tag-taigen-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>TaiGen and Joincare Partner on TG\u20114318 DPP1 Inhibitor for Bronchiectasis in Greater China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"TaiGen Biotechnology and Joincare Pharmaceutical Group (SHA: 600380) announced a licensing agreement for the collaborative development and commercialization of TG\u20114318, a novel Dipeptidyl Peptidase 1 (DPP1) inhibitor for bronchiectasis, covering Greater China (Mainland China, Hong Kong, and Macau).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55225\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TaiGen and Joincare Partner on TG\u20114318 DPP1 Inhibitor for Bronchiectasis in Greater China\" \/>\n<meta property=\"og:description\" content=\"TaiGen Biotechnology and Joincare Pharmaceutical Group (SHA: 600380) announced a licensing agreement for the collaborative development and commercialization of TG\u20114318, a novel Dipeptidyl Peptidase 1 (DPP1) inhibitor for bronchiectasis, covering Greater China (Mainland China, Hong Kong, and Macau).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55225\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-22T21:58:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T21:58:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55225#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55225\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"TaiGen and Joincare Partner on TG\u20114318 DPP1 Inhibitor for Bronchiectasis in Greater China\",\"datePublished\":\"2026-01-22T21:58:02+00:00\",\"dateModified\":\"2026-01-22T21:58:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55225\"},\"wordCount\":334,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Joincare Pharmaceutical\",\"SHA: 600380\",\"TaiGen Biotechnology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55225#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55225\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55225\",\"name\":\"TaiGen and Joincare Partner on TG\u20114318 DPP1 Inhibitor for Bronchiectasis in Greater China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-22T21:58:02+00:00\",\"dateModified\":\"2026-01-22T21:58:03+00:00\",\"description\":\"TaiGen Biotechnology and Joincare Pharmaceutical Group (SHA: 600380) announced a licensing agreement for the collaborative development and commercialization of TG\u20114318, a novel Dipeptidyl Peptidase 1 (DPP1) inhibitor for bronchiectasis, covering Greater China (Mainland China, Hong Kong, and Macau).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55225#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55225\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55225#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TaiGen and Joincare Partner on TG\u20114318 DPP1 Inhibitor for Bronchiectasis in Greater China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"TaiGen and Joincare Partner on TG\u20114318 DPP1 Inhibitor for Bronchiectasis in Greater China - Insight, China&#039;s Pharmaceutical Industry","description":"TaiGen Biotechnology and Joincare Pharmaceutical Group (SHA: 600380) announced a licensing agreement for the collaborative development and commercialization of TG\u20114318, a novel Dipeptidyl Peptidase 1 (DPP1) inhibitor for bronchiectasis, covering Greater China (Mainland China, Hong Kong, and Macau).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55225","og_locale":"en_US","og_type":"article","og_title":"TaiGen and Joincare Partner on TG\u20114318 DPP1 Inhibitor for Bronchiectasis in Greater China","og_description":"TaiGen Biotechnology and Joincare Pharmaceutical Group (SHA: 600380) announced a licensing agreement for the collaborative development and commercialization of TG\u20114318, a novel Dipeptidyl Peptidase 1 (DPP1) inhibitor for bronchiectasis, covering Greater China (Mainland China, Hong Kong, and Macau).","og_url":"https:\/\/flcube.com\/?p=55225","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-22T21:58:02+00:00","article_modified_time":"2026-01-22T21:58:03+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55225#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55225"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"TaiGen and Joincare Partner on TG\u20114318 DPP1 Inhibitor for Bronchiectasis in Greater China","datePublished":"2026-01-22T21:58:02+00:00","dateModified":"2026-01-22T21:58:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55225"},"wordCount":334,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Joincare Pharmaceutical","SHA: 600380","TaiGen Biotechnology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55225#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55225","url":"https:\/\/flcube.com\/?p=55225","name":"TaiGen and Joincare Partner on TG\u20114318 DPP1 Inhibitor for Bronchiectasis in Greater China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-22T21:58:02+00:00","dateModified":"2026-01-22T21:58:03+00:00","description":"TaiGen Biotechnology and Joincare Pharmaceutical Group (SHA: 600380) announced a licensing agreement for the collaborative development and commercialization of TG\u20114318, a novel Dipeptidyl Peptidase 1 (DPP1) inhibitor for bronchiectasis, covering Greater China (Mainland China, Hong Kong, and Macau).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55225#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55225"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55225#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"TaiGen and Joincare Partner on TG\u20114318 DPP1 Inhibitor for Bronchiectasis in Greater China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55225"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55225\/revisions"}],"predecessor-version":[{"id":55228,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55225\/revisions\/55228"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}